ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab’)2
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07167-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Wenpeng Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist., Beijing, 100034, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antigens, Neoplasm, Copper Radioisotopes, Cell Adhesion Molecules. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital, The Henan Association for Science and Technology Youth Talent Support Program, Henan Medical Science and Technology Research Program Joint Construction Project.
Abstract (Originalsprache)
PURPOSE: The Trop2-targeting antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) has demonstrated remarkable efficacy in patients with metastatic triple-negative breast cancer (TNBC). ImmunoPET imaging offers a noninvasive method to visualize the expression and distribution of target antigens in vivo. In this study, we developed F(ab')2 fragments of Trodelvy for immunoPET imaging to detect Trop2 expression in TNBC models, aiming to achieve a shorter imaging window. MATERIALS AND METHODS: Trodelvy-F(ab')2 was prepared using the IdeS protease kit and purified with Magne Protein A beads and MagneHis™ Ni Particles. The products were characterized by non-reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis and high-performance liquid chromatography. Trodelvy-F(ab')2 was subsequently conjugated with p-SCN-Bn-NOTA (NOTA) for radiolabeling with 64Cu. ImmunoPET imaging using [64Cu]Cu-NOTA-Trodelvy-F(ab')2 was conducted at multiple time points to assess its in vivo targeting capability. Immunohistochemical and immunofluorescence analyses were performed on tumor tissues obtained from tumor-bearing mice. RESULTS: The radiochemical yield of [64Cu]Cu-NOTA-Trodelvy-F(ab')2 exceeded 90%, with a radiochemical purity greater than 99%. High Trop2 expression was observed in MDA-MB-468 cells, whereas MDST8 cells exhibited low expression. The apparent dissociation constant (KD) of [64Cu]Cu-NOTA-Trodelvy-F(ab')2 for MDA-MB-468 cells was determined to be 14.60 nM. ImmunoPET imaging revealed clear uptake of [64Cu]Cu-NOTA-Trodelvy-F(ab')2 in MDA-MB-468 tumors as early as 4 h post-injection (p.i.) (8.20 ± 0.98%ID/g), peaking at 12 h p.i. (11.13 ± 0.45%ID/g). Uptake was significantly higher compared to the MDST8 group (3.37 ± 0.45%ID/g at 4 h; 5.77 ± 0.74%ID/g at 12 h) and the blocking group (2.67 ± 0.21%ID/g at 4 h; 3.07 ± 0.37%ID/g at 12 h). [64Cu]Cu-NOTA-Trodelvy-F(ab')2 achieved significantly higher tumor-to-heart ratios in MDA-MB-468 tumors (3.87 ± 0.58 vs. 0.74 ± 0.19, P = 0.0019) at 12 h p.i., compared to [64Cu]Cu-NOTA-Trodelvy, indicating superior tumor contrast. CONCLUSIONS: Our findings indicate that [64Cu]Cu-NOTA-Trodelvy-F(ab')2 exhibits rapid, specific, and sustained tumor accumulation in TNBC models, enabling precise and noninvasive monitoring of Trop2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist., Beijing, 100034, China.
- Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, 100730, China.
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China.
- Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA.
- Department of Urology, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist., Beijing, 100034, China. Dantefanbmu@pku.edu.cn.
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China. perfect1989a@163.com.
ORCID-Profile: Weibo Cai
Förderung
- Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital
- The Henan Association for Science and Technology Youth Talent Support Program
- Henan Medical Science and Technology Research Program Joint Construction Project
- NCI NIH HHS
- Beijing Municipal Science & Technology Commission
- The Key Research Project in Henan Universities
- the Scientific and technological project in Henan Province
- Beijing Nova Program
Zitieren
APA
Huang, W., Zhang, Y., Xiao, X., Yang, Q., Mixdorf, J. C., Sun, X., Engle, J. W., Fan, Y., Li, L., Kang, L., & Cai, W. (2025). ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab’)2. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07167-5
Vancouver
Huang W, Zhang Y, Xiao X, Yang Q, Mixdorf JC, Sun X, et al. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab’)2. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07167-5
BibTeX
@article{Huang2025,
author = {Huang, Wenpeng and Zhang, Yuwei and Xiao, Xiaoyan and Yang, Qi and Mixdorf, Jason C and Sun, Xinyao and Engle, Jonathan W and Fan, Yu and Li, Liming and Kang, Lei and Cai, Weibo},
title = {ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab’)2},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07167-5}
}
EUVIMED